Biotech Co.*
(Country;
Symbol)

Pharma Co.
(Country)

Product

Terms/Details (Date)


Advancis
Pharmaceutical
Corp.
(AVNC)

Innovex (unit of Quintiles Transnational Corp.)

Innovex will provide sales and marketing services for Advancis' cephalosporin antibiotic, Keflex capsules

Innovex will deploy 75 sales representatives to sell and promote the recently approved product under a two-year deal; terms were not disclosed (6/22)

Amaxa GmbH*
(Germany)

Dharmacon Inc.
(unit of Fisher
Biosciences)

Deal to co-promote data generated using Dharmacon's siRNA libraries with Amaxa's Nucleofector technology

The focus is on delivery of siRNA into primary cells and non-standard cell lines; terms of the deal were not disclosed (6/6)

Antigenics
Inc.
(AGEN)

GlaxoSmithKline Biologicals (Belgium)

They expanded deal under which Antigenics supplies QS-21 Stimulon adjuvant for use in GSK vaccines

Antigenics also will transfer manufacturing technologies to GSK under the agreement; Antigenics is entitled to milestone and royalty payments in the deal (7/10)

Cephalon
Inc.
(CEPH)

Takeda Pharmaceuticals North America Inc.

Takeda will co-promote Cephalon's Provigil in the U.S. (and Nuvigil, if approved)

Takeda will provide 500 sales reps, adding to the 400 from Cephalon; Takeda is entitled to royalties under the three-year, renewable deal (6/12)

Generex
Biotechnology
Corp.
(Canada;
GNBT)

Cardinal Health Inc.

Deal under which Cardinal will manufacture clinical-trial batches of Generex's Oral-lyn insulin spray product

Terms of the deal were not disclosed (6/22)

Genomatica Inc.*

DSM Biologics (the Netherlands)

Multiyear deal under which Genomatica will help DSM develop improved biological processes

The deal centers around implementation of Genomatica's metabolic modeling and simulation technologies; Genomatica is entitled to license fees, R&D payments and milestone payments in the deal (6/28)

Nastech
Pharmaceutical
Co. Inc.
(NSTK)

Procter & Gamble Pharmaceuticals Inc.

Nastech will manufacture PTH1-34 nasal spray for P&G

The supply agreement is in addition to a collaboration on the parathyroid hormone-based product the companies entered in February (6/6)

SciClone
Pharmaceuticals
Inc.
(SCLN)

Biocompatibles International plc (UK)

SciClone got exclusive rights to market Biocompatibles' DC Bead chemotherapy-releasing device in China

A submission for approval in China is planned during 2006; terms of the three- year deal were not disclosed (6/9)

Stellar
Pharmaceuticals
Inc.
(Canada;
CDNX:SLX)

Bio-Technic Romania Srl (Romania)

Bio-Technic got rights to the hyaluronate-based product NeoVisc in Romania

The product is used to treat the pain of osteoarthritis; terms of the deal were not disclosed (7/13)

Tercica Inc.
(TRCA)

Biologix FZ Co. (Lebanon) and Giddi Pharma Co. (Taiwan)

Separate deals were entered covering the distribution of Tercica's growth hormone product Increlex

Biologix FZ will distribute the product in 17 Middle East and North African countries, and Giddi will distribute it in Taiwan; terms were not disclosed (6/14)

Tm Bioscience
Corp.
(Canada;
TSE:TMC)

Sanbio BV (the Netherlands)

Sanbio will commercialize the ID-Tag Respiratory Viral Panel in the Netherlands

The product is used in the diagnosis of respiratory viruses; terms of the distribution deal were not disclosed (6/16)


Notes:

# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

CDNX = Canadian Venture Exchange; TSE = Toronto Stock Exchange.